Retatrutide may well be the therapy that bridges the gap between cutting-edge research and real-world transformationsignaling the future of personalized metabolic care
There are three GLP-1 drugs that the FDA has approved for the treatment of obesity: Zepbound (tirzepatide), Saxenda (liraglutide), and Wegovy (semaglutide)
CONTACT US: Email: [email protected] 345 Park Avenue South New York, NY 10010 About Cure: Cure is a healthcare innovation campus in the heart of New York City that features laboratory and business facilities, a collaboration residency, office space and premium event venues, including an education center, conference center, and iconic rooftop facility, as well as tools, mentoring, networking, and other assistance to members of its ecosystem
9,10 Summary A large body of high-quality evidence suggests that in patients with obesity without diabetes, GLP-1 and GIP/GLP-1 receptor agonists are associated with significant regain of lost weight after therapy discontinuation
